Intas Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Intas Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012303
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and markets pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma derived product based therapies. It has nine formulation manufacturing facilities and two active pharmaceutical ingredient (API) and intermediate facilities in India. The company markets its products globally through internal sales force and a network of distributors. Intas is headquartered in Ahmedabad, Gujarat, India.

Intas Pharmaceuticals Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Intas Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Teva Pharma May Sell European Oncology and Pain Assets 13
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 15
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 16
Intas Pharma to Acquire Gujarat-based Biotechnology Unit of RPG Life Sciences for USD3.7 Million 18
Intas Pharma Acquires Hospital Business of Combino Pharm 19
Private Equity 20
Capital International Acquires 3% Stake in Intas Pharma from ChrysCapital for USD106 Million 20
Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 21
ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For US$56.1 Million 22
ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For US$56 Million 23
Partnerships 24
Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 24
Licensing Agreements 25
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 25
Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 26
Equity Offering 27
Intas Pharma Files Registration Statement For IPO To Raise Up To US$200 Million 27
Acquisition 28
Accord Healthcare Acquires Essential Pharma 28
Intas Pharmaceuticals Ltd – Key Competitors 29
Intas Pharmaceuticals Ltd – Key Employees 30
Intas Pharmaceuticals Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Intas Pharmaceuticals Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Intas Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Teva Pharma May Sell European Oncology and Pain Assets 13
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 15
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 16
Intas Pharma to Acquire Gujarat-based Biotechnology Unit of RPG Life Sciences for USD3.7 Million 18
Intas Pharma Acquires Hospital Business of Combino Pharm 19
Capital International Acquires 3% Stake in Intas Pharma from ChrysCapital for USD106 Million 20
Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 21
ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For US$56.1 Million 22
ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For US$56 Million 23
Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 24
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 25
Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 26
Intas Pharma Files Registration Statement For IPO To Raise Up To US$200 Million 27
Accord Healthcare Acquires Essential Pharma 28
Intas Pharmaceuticals Ltd, Key Competitors 29
Intas Pharmaceuticals Ltd, Key Employees 30
Intas Pharmaceuticals Ltd, Other Locations 31
Intas Pharmaceuticals Ltd, Subsidiaries 32

★海外企業調査レポート[Intas Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Daicel Corp (4202):企業の財務・戦略的SWOT分析
    Daicel Corp (4202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Jubilant Life Sciences Ltd (JUBILANT):製薬・医療:M&Aディール及び事業提携情報
    Summary Jubilant Life Sciences Ltd (Jubilant) is an integrated pharmaceutical and life sciences company that provides pharmaceuticals, life science ingredients and drug discovery solutions. The company’s product portfolio includes radiopharmaceuticals, allergy therapy products, active pharmaceutical …
  • Green’s General Foods Pty Ltd:企業の戦略・SWOT・財務情報
    Green’s General Foods Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Green’s General Foods Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Passenger Rail Agency of South Africa:企業の戦略的SWOT分析
    Passenger Rail Agency of South Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • STATS UK Ltd:企業の戦略的SWOT分析
    STATS UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • ams AG (AMS):企業の財務・戦略的SWOT分析
    Summary ams AG (ams) involves in manufacturing and marketing of semiconductor products. The offers various company's which include ultra small ANC speaker driver, environmental sensors, spectral sensing, CMOS imaging sensors, DC-DC boost converters and CT and digital X-ray . It offers power manageme …
  • Investment Technology Group, Inc.
    Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Perrigo Company Plc (PRGO)-医療機器分野:企業M&A・提携分析
    Summary Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutic …
  • Bank of Ireland:戦略・SWOT・企業財務分析
    Bank of Ireland - Strategy, SWOT and Corporate Finance Report Summary Bank of Ireland - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Hanwei Energy Services Corp (HE):企業の財務・戦略的SWOT分析
    Summary Hanwei Energy Services Corp (Hanwei Energy) is a chemical company that develops, manufactures and distributes plastic fibre reinforced piping systems. The company’s products include anhydride and amine cured frp pipes, fittings, fixtures and flanges. It offers client solutions such as pre-te …
  • GenomeDx Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary GenomeDx Biosciences Inc (GenomeDx) is a genomic information company developing solutions for prostate cancer treatment and the management of other urologic cancers. The company offers decipher prostate cancer classifier, a transformative genomic test that provides an assessment of tumor agg …
  • Cholamandalam Investment and Finance Company Ltd (CHOLAFIN):企業の財務・戦略的SWOT分析
    Cholamandalam Investment and Finance Company Ltd (CHOLAFIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …
  • CardioGenics Inc:企業の製品パイプライン分析2018
    Summary CardioGenics Inc (CardioGenics), a subsidiary of CardioGenics Holdings Inc is a medical device company that manufactures sensitive diagnostic test products to the in-vitro diagnostics market. The company’s products include QL care analyzer, immunoassay tests, and paramagnetic beads, among ot …
  • MAXONS Restorations Inc:企業の戦略的SWOT分析
    MAXONS Restorations Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Neurones SA (FR0004050250NRO):企業の財務・戦略的SWOT分析
    Neurones SA (FR0004050250NRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Sunoco Logistics Partners L.P.:企業のM&A・事業提携・投資動向
    Sunoco Logistics Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sunoco Logistics Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Tec-Masters, Inc.:企業の戦略・SWOT・財務情報
    Tec-Masters, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tec-Masters, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Kancera AB (KAN):企業の財務・戦略的SWOT分析
    Summary Kancera AB (Kancera) is a developer of drug candidates for the treatment of cancer. The company’s pipeline products include fractalkine inhibitor AZD8797, used to stop tumor growth; small molecule HDAC6 inhibitors, for neutralizing blood cancer; small molecule PFKFB3 inhibitors, for stopping …
  • Clevexel Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Clevexel Pharma SAS (Clevexel) is a pharmaceutical company that develops drugs for the treatment of central nervous system diseases. The company’s pipeline product candidate includes CVXL-0107, a glutamate release inhibitor developed to improve the quality of life for Parkinson’s disease pat …
  • Aecon Group Inc (ARE):企業の財務・戦略的SWOT分析
    Aecon Group Inc (ARE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆